|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||40.67 - 40.67|
|52 Week Range||31.22 - 43.06|
|Beta (3Y Monthly)||1.08|
|PE Ratio (TTM)||25.06|
|Forward Dividend & Yield||1.65 (4.12%)|
|1y Target Est||N/A|
Local rare disease drugmaker Sarepta Therapeutics Inc. is expanding its efforts in the gene therapy field, signing a deal this week with a North Carolina startup to develop up to eight new treatments.
The CAR-T wave has died down among biotech investors, but Takeda Pharmaceuticals could help reinvigorate the space with its venture into CAR-NK. Continue reading...
Takeda Pharmaceutical Co's experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but it failed to protect against one type of the virus in people with no prior exposure to dengue. Takeda's vaccine was 80.2% effective at preventing dengue among children and teens in the year after they got the shot, according to results of a Phase III study published in the New England Journal of Medicine on Wednesday. Sanofi's Dengvaxia - the world's first dengue vaccine - had demonstrated 59.2% overall efficacy in the first year of follow-up based on combined results from two late-stage trials.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
New biopharma startup Cyclerion Therapeutics has stumbled out of the gate, disclosing Wednesday that one of its lead drug candidates failed in a mid-stage study.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 21.) Aprea Therapeutics Inc (NASDAQ: APRE ) AVITA ...
Takeda Pharmaceutical Co. Ltd. is shedding dozens of products and an undisclosed number of employees in a $200 million deal. But the Japanese drugmaker is reviving plans to occupy Cambridge’s iconic Genzyme building.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Takeda Pharmaceutical Company Limited and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 14.) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals ...
Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million. The sale, which Takeda said in a statement is expected to close in the quarter ending March, comes as Japan's biggest drugmaker looks to trim its debt following the $59 billion purchase of Shire.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]
The pace of acquisitions in the biotech industry is expected to accelerate as big pharma seeks to boost growth Continue reading...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The ...
− Takeda UK Ltd. is pleased to announce that NICE has recommended the use of Takhzyro® ▼ (lanadelumab) subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 5) Bioanalytical Systems, Inc. (NASDAQ: BASI ) NextCure ...
FRANKFURT/LONDON (Reuters) - Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters. Takeda is hoping to fetch around 1.5 billion euros ($1.68 billion) from the sale and has sent out information packages to interested parties, the sources said. The drugs on the block include over-the-counter (OTC) and prescription medicines, patents for most of which have run out, meaning they can be copied by generic drug makers.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals ...